Risk of venous thromboembolism in patients with rheumatoid arthritis

Arthritis Care and Research

Volumn 65, Issue 10, 2013, Pages 1600-1607

  Kim, Seoyoung C ^a   Schneeweiss, Sebastian ^a   Liu, Jun ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ORAL CONTRACEPTIVE AGENT; STEROID;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEART FAILURE; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PREGNANCY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; VENOUS THROMBOEMBOLISM;

ADULT; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84884998871     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22039     Document Type: Article

References (36)

1. White RH,. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-8.
2. Anderson FA Jr, Spencer FA,. Risk factors for venous thromboembolism. Circulation 2003; 107: I9-16.
3. Goldhaber SZ, Bounameaux H,. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379: 1835-46.
4. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69: 1920-5.
5. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
6. Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A,. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48: 1833-40.
7. Van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009; 68: 1395-400.
8. Fox EA, Kahn SR,. The relationship between inflammation and venous thrombosis: a systematic review of clinical studies. Thromb Haemost 2005; 94: 362-5.
9. Van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-7.
10. Folsom AR, Lutsey PL, Astor BC, Cushman M,. C-reactive protein and venous thromboembolism: a prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-9.
11. Luxembourg B, Schmitt J, Humpich M, Glowatzki M, Dressler D, Seifried E, et al. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: a focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost 2009; 102: 668-75.
12. Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL,. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012; 64: 53-61.
13. Matta F, Singala R, Yaekoub A, Najjar R, Stein PD,. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101: 134-8.
14. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ,. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 2011; 9: 1.
15. Johannesdottir SA, Schmidt M, Horvath-Puho E, Sorensen HT,. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2012; 10: 815-21.
16. Zoller B, Li X, Sundquist J, Sundquist K,. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379: 244-9.
17. Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Avina-Zubieta JA, Zhang Y,. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis 2013; 72: 1182-7.
18. Holmqvist M, Neovius M, Eriksson J, Mantel A, Wallberg-Jonsson S, Jacobsson LT, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 2012; 308: 1350-6.
19. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011; 13: R32.
20. White RH, Garcia M, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 2010; 126: 61-7.
21. Tagalakis V, Kahn SR,. Determining the test characteristics of claims-based diagnostic codes for the diagnosis of venous thromboembolism in a medical service claims database. Pharmacoepidemiol Drug Saf 2011; 20: 304-7.
22. Deyo R, Cherkin D, Ciol M,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
23. Schneeweiss S, Seeger J, Maclure M, Wang PS, Avorn J, Glynn RJ,. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-64.
24. Glynn RJ, Rosner B,. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 2005; 162: 975-82.
25. Rothman K, Greenland S, Lash T,. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
26. Cox D,. Regression models and life-tables. J R Stat Soc 1972; 34: 187-220.
27. Zoller B, Li X, Sundquist J, Sundquist K,. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis 2012; 2: 171-83.
28. Anderson FJ, Wheeler H,. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg 1992; 16: 707-14.
29. Nicolaides AN, Irving D,. Clinical factors and the risk of deep venous thrombosis. In:, Nicolaides AN, editor. Thromboembolism: etiology, advances in prevention, and management. Baltimore (MD): University Park Press; 1975. p. 193-204.
30. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med 1991; 151: 933-8.
31. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III,. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-93.
32. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-8.
33. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10: 1019-25.
34. Schneeweiss S, Avorn J,. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-37.
35. Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011; 63: 877-83.
36. Makol A, Grover M, Guggenheim C, Hassouna H,. Etanercept and venous thromboembolism: a case series. J Med Case Rep 2010; 4: 12.